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Resolvins are endogenous lipid mediators derived from omega-3 fatty acids. Resolvin 
E1 (RvE1), derived from eicosapentaenoic acid (EPA), modulates osteoclasts and 
immune cells in periodontal disease models. The direct role of RvE1 in bone remodeling 
is not well understood. The objective of this study was to determine the impact of RvE1 
on bone remodeling under inflammatory conditions. Our working hypothesis is that RvE1 
downregulates bone resorption through direct actions on both osteoblast and osteoclast 
function in inflammatory osteoclastogenesis. A tumor necrosis factor-α induced local 
calvarial osteolysis model with or without the systemic administration of RvE1 was used. 
To evaluate osteoclastogenesis and NFκB signaling pathway activity, murine bone tissue 
was evaluated by Micro CT (μCT) analysis, TRAP staining, and immunofluorescence 
analysis. Mechanistically, to evaluate the direct role of RvE1 impacting bone cells, pri-
mary calvarial mouse osteoblasts were stimulated with interleukin (IL)-6 (10 ng/ml) and 
IL-6 receptor (10 ng/ml) and simultaneously incubated with or without RvE1 (100 nM). 
Expression of receptor activator of NFκB ligand (RANKL) and osteoprotegerin (OPG) was 
measured by ELISA. RNA sequencing (RNA-Seq) and differential expression analysis 
was performed to determine signaling pathways impacted by RvE1. The systemic admi-
nistration of RvE1 reduced calvarial bone resorption as determined by µCT. Histologic 
analysis of calvaria revealed that osteoclastogenesis was reduced as determined by 
number and size of osteoclasts in TRAP-stained sections (p < 0.05). Immunofluorescence 
staining of calvarial sections revealed that RvE1 reduced RANKL secretion by 25% 
(p < 0.05). Stimulation of osteoblasts with IL-6 increased RANKL production by 30% 
changing the RANKL/OPG to favor osteoclast activation and bone resorption. The ratio 
changes were reversed by 100 nM RvE1. RvE1 decreased the production of RANKL 
maintaining an RANKL/OPG more favorable for bone formation. RNA-Seq and tran-
scriptomic pipeline analysis revealed that RvE1 significantly downregulates osteoclast 
differentiation mediated by differential regulation of NFκB and PI3K–AKT pathways. RvE1 
reduces inflammatory bone resorption. This action is mediated, at least in part, by direct 
actions on bone cells promoting a favorable RANKL/OPG ratio. Mediators of resolution 
in innate immunity also directly regulate bone cell gene expression that is modulated by 
RvE1 through at least 14 specific genes in this mouse model.
Keywords: resolvin e1, tissue regeneration, bone, resolution, bone metabolism, inflammatory diseases
FigUre 1 | (a) RvE1 reduces osteoclastogenesis triggered by TNF-α injections. TRAP-positive multinucleated giant cells (MNGCs) were counted in each section 
and the mean number of nuclei/cell/section was calculated by dividing the number of nuclei by the number of MNGCs found in each section. Statistically significant 
increases in numbers of MNGCs and nuclei/MNGC/section were measured in sections from samples receiving supracalvarial TNF-α injections when compared to 
samples receiving PBS injections (p < 0.05). Statistically significant decrease in both values was found in samples from animals treated with daily injections of RvE1 
when compared to the TNF-α only group (p < 0.05). (B) Protective role of resolvin E1 (RvE1) in murine calvariae. Significant increases in the surface porosity  
(SP)/bone volume (BV) ratio was noted in specimens from the tumor necrosis factor-α (TNF-α) group when compared to the negative control and RvE1 treatment 
group (n = 3, p < 0.05). Reconstruction was performed using Amira 3D software. BV and SP measurements were calculated using the same software. SP/BV 
measurements were calculated to standardize the surface area being examined for porosity. Results are expression of the mean SP/BV ratio. *p < 0.05 vs. control. 
##p < 0.05 vs. active control.
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inTrODUcTiOn
The niche mediators and cells shaping metabolic control of bone 
tissue tightly regulate bone-remodeling circuitry. The coupling 
activities between mesenchymal origin bone forming cells, osteo-
blasts, with the myeloid origin bone resorbing cells, osteoclasts, 
are modulated by receptor activator of NFκB ligand (RANKL) 
and osteoprotegerin (OPG) biological actions (1, 2).
Inflammatory cytokines produced by osteoblasts and osteo-
clasts, including interleukin (IL)-1, IL-6, and tumor necrosis 
factor-α (TNF-α), activate the bone microenvironment, boost-
ing expression of RANK and bone resorption phenotype (3). 
In chronic inflammatory conditions including periodontitis and 
rheumatoid arthritis, persistent chronic inflammation leads to 
loss of bone mass and volume, and is consistently accompanied 
by an increase in local expression of RANKL (4–8). Long and 
craniofacial bones are targets of unresolved inflammation and 
clinical consequences affect populations worldwide. An estim-
ated 47% of the US population suffers from moderate to severe 
periodontal disease (9–11). According to the United Nations and 
WHO, musculoskeletal conditions (rheumatoid arthritis, osteo-
porosis, and osteoarthritis) are a major burden financially and 
socially on individuals, health systems, and social care systems 
(12). Thus, understanding activation and resolution (termina-
tion) of inflammation has potential impact in bone metabolism 
and human health.
Immune cells are regulated by specialized pro-resolving medi-
ators (SPMs) (13–15), which were first characterized by unbiased 
systems approach to study acute inflammation and self-resolving 
inflammatory exudates (16, 17). A new genus of molecules was 
identified: lipoxins, resolvins, maresins, and protectins (colle-
ctively, SPMs) (18–20). Temporal lipoxygenase class-switching 
FigUre 2 | (a) Receptor activator of NFκB ligand (RANKL) and osteoprotegerin (OPG) balance is rescued by resolvin E1 (RvE1). Representative 
immunofluorescence imaging of primary RANKL monoclonal mouse antibodies conjugated with Alexa Fluor488. Evaluation of Immunofluorescence of histology 
sections in the different groups was conducted by taking 20× and 40× images and using Image J software to compare intensity of fluorescence in medullary areas. 
The mean immunofluorescence levels were then calculated and compared across groups. In the RvE1 treatment group, mean RANKL immunofluorescence was 
lower than the tumor necrosis factor-α (TNF-α) group (p < 0.05). The same slides stained with Alexa Fluor488 for RANKL immunofluorescence were also double 
stained with primary OPG monoclonal mouse antibodies conjugated with Dylight550 dye. Evaluation of mean OPG immunofluorescence values revealed no 
statistically significant differences between all three groups (p > 0.05). (B) Secreted RANKL and OPG are influenced by RvE1. The results demonstrate that RvE1 
suppresses levels of RANKL via direct action on osteoblasts leading to a shift in the RANKL/OPG ratio in favor of bone preservation and formation. RvE1 at 100 nM 
significantly decreased RANKL production by osteoblasts stimulated by interleukin (IL)-6 (p < 0.02). Results are expressed as mean of RANKL and OPG levels. 
*p < 0.05 vs. control. ##p < 0.05 vs. active control.
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results in the emergence of lipoxins, derived from arachidonic 
acid, and resolvins, maresins, and protectins, derived from 
omega-3 fatty acids that drive resolution of inflammation and 
clearance of inflammatory lesions (15, 21). Inflammation reso-
lution is not a passive mechanism resulting from decay of pro-
inflammatory cytokines; instead, SPMs are active biochemical 
signaling molecules (14, 15, 22, 23) promoting debris and apop-
totic cell clearance through lymphatics and a return to homeo-
stasis. Resolvin E1 (RvE1) is derived from eicosapentaenoic acid 
(EPA), and along with the other mediators has been shown to 
have a modulatory role in inflammation-associated models of 
human diseases (24–28), including arthritis (29), colitis (30), peri-
tonitis (14, 31), asthma (19, 24, 32), dermatitis (33), infantile eczema 
(34), diabetic wounds (35, 36), and retinopathies (37, 38).
The purpose of this study was to determine the mechanism 
of RvE1 actions in the prevention of bone resorption on a subcel-
lular level. To build on our previous experiments, we used an 
in vivo model of bone resorption, rather than an artificial in vitro 
assay (the pit assay of dentin slices) (39) to characterize the 
RANKL/OPG axis in situ and at the molecular level. Specifically, 
the transcriptome of the osteoblast in inflammation was assessed 
with and without treatment with RvE1.
MaTerials anD MeThODs
animals
All experiments in this study were reviewed and approved by 
the Institutional Animal Care and Use Committee (IACUC) of 
FigUre 3 | Gene expression shift with resolvin E1 (RvE1) treatment. A heat map of top 100 differentially expressed genes (absolute log2 fold change) compares 
OB + interleukin (IL)-6 vs. OB alone, OB + IL-6 + RvE1 vs. OB alone, and OB + IL-6 + RvE1 vs. cells + IL-6. The color intensity reflects the level of log2 fold change for 
each comparison with red for upregulation and blue for downregulation. Fainter colors indicate lesser changes in gene expression between the groups being compared. 
Genes were ordered based on a dendrogram derived from hierarchical clustering of log2 values of all rows; genes with similar differential expression patterns were 
grouped together. The result demonstrates a remarkable mirror image change in gene expression. Results are expressed as mean of genes highly expressed.
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the Forsyth Institute. Eighteen 5- to 6-week-old C57BL/6 mice 
(Charles River Laboratories, New York, NY, USA) were used for 
each experiment.
Osteolysis Model
Mice were divided into three groups (control group, receiving 
PBS, calvarial injections: n = 6, TNF-α group, receiving TNF-α 
calvarial injections: n = 6, TNF-α + RvE1 group, receiving TNF-α 
calvarial injections + RvE1 intraperitoneal injections: n = 6). Mice 
were sedated with isoflurane 2–3% before being anesthetized with 
ketamine (80 mg/kg intraperitoneally) and xylazine (16 mg/kg, 
intraperitoneally). Daily supracalvarial injections of 100  µl of 
PBS or TNF-α (2 μg/100 μl) with or without daily intraperitoneal 
injections of 50 ng of RvE1 were performed for 7 days in six mice 
per group. Mice were sacrificed at the end of the experimental 
period (day 8), and all calvariae were dissected immediately after 
sacrifice. One calvarium from each group was defleshed with 
dermestid beetles for 24 h and processed for photographic imag-
ing. The other five calvariae in each group were fixed overnight 
with 4% paraformaldehyde at 4°C.
Recombinant mouse TNF-α was purchased from R&D 
systems (Minneapolis, MN, USA). RvE1 (C20H30O5, molecular 
weight: 350.5, purity >97%, λmax: 272 nm) was purchased from 
Cayman Chemical (Ann Arbor, MI, USA). The RvE1 provided 
by Cayman was prepared by stereospecific total synthesis guided 
by the published structure described by Arita et al. (30). RANKL 
antibody conjugated with Alexa Fluorochrome 488, and OPG 
and IL-6 antibodies both conjugated with Dylight fluorochrome 
550 were purchased from Novus Biologicals (Littleton, CO, 
USA). Specimens were demineralized in 10% EDTA for 4 days 
at 4°C. To count osteoclast number, the sections were stained for 
TRAP activity, and counterstained with hematoxylin. Sections for 
immunofluorescence were deparaffinized and incubated for 1 h 
with a mix of primary antibodies at designated concentrations. 
Slides were then viewed under fluorescent light and images were 
taken using Zeiss software.
Osteoblast isolation
Neonatal mice calvarial osteoblasts were isolated following the 
protocol of Wong and Cohn (40) from mouse litters (7–8 mice, 
2–4  days old) by sequential incubation in collagenase type 2 
solution (Worthington). Isolated primary cells were grown in 
two 75 ml flasks and after reaching 90% confluence were passaged 
into six-well plates at a density of 6 × 104 cells/well. Medium was sup-
plemented with vitamin D3 and ascorbic acid and was changed 
every other day for 10 days (41).
rna isolation
Total RNA was isolated from murine osteoblasts with TriZol 
(Life Technologies, Carlsbad, CA, USA) (42), and purity was 
FigUre 4 | Continued
FigUre 4 | Osteoclast differentiation pathway perturbation after stimulation with interleukin (IL)-6 with or without resolvin E1 (RvE1). Using Illumina’s iPathwayGuide 
application, a significant perturbation in the osteoclast differentiation pathway was noted after stimulation of osteoblasts with IL-6. Upregulation of IL-1 lead to 
promotion of downstream signaling affecting the MAPK and NFκB signaling pathways leading to upregulation of osteoclast differentiation. After treatment with  
RvE1, downregulation of STAT1 led to inhibition of downstream signaling affecting the MAPK and NFκB signaling pathways leading to downregulation of  
osteoclast differentiation.
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confirmed using a NanoDrop ND-1000 spectrop hotometer 
(Thermo Scientific). RNA was stored for later use at −80°C in 
RNAlater. RNA was then reverse transcribed using a High 
Capacity cDNA Reverse Transcription Kit (Applied Bio systems). 
mRNA expression levels were quantified by real-time PCR using 
SYBR Select Master Mix (Applied Biosystems) on a Light Cycler 
480 (Roche Diagnostics).
rna sequencing (rna-seq)
Cells were collected immediately after the experiment was com-
pleted and processed for RNA-Seq on the Illumina Basespace 
platform. Total RNA was extracted from osteoblasts using an 
RNeasy Mini kit (Qiagen, Valencia, CA, USA). Raw read counts 
per gene were mapped to corresponding human homologs, using 
homology information from the Mouse Genome Informatics 
database (The Jackson Laboratory). The iPathwayGuide was 
used to score the biological pathways using impact analysis (43, 
44). Impact analysis uses two values to measure magnitude of 
pathway being examined (1) the overrepresentation of differen-
tially expressed genes in a pathway and (2) the perturbation of 
that pathway computed by propagating the measured expression 
chan ges across the pathway topology. These aspects are captured 
independent probability values; pORA, representing the prob-
ability of obtaining a number of differentially expressed genes 
on the given pathway greater or equal to chance observations; 
pAcc, represents the p-value obtained from total perturbation 
accumulation. Combining pORA and pAcc is done to produce 
a unique global p value using Fisher’s method, which is then 
corrected for multiple comparisons using the false discovery rate 
method.
immunofluorescence
Calvarial sections were incubated with anti-Fc receptor (BD) 
blocking antibody (5  µg/ml  ×  106 cells, 15  min) and then 
labeled with anti-human RANKL Alexa Fluor 488-conjugated 
antibody (10 µg/ml × 106 cells, 1 h at RT) or OPG PE-conjugated 
FigUre 5 | Pathway impact analysis. Using Illumina’s iPathwayGuide, we 
identified the biological pathways with the most significant perturbation and 
overrepresentation combination. Extracellular matrix (ECM) receptors 
interactions pathway was the most significantly affected.
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antibody isotype control, R&D System. Expression levels of 
the proteins were monitored by microscopy and analyzed with 
NIH Image J.
elisa
Cells were cultured for 10  days as described above and then 
stimulated with 10 ng/ml IL-6 and 10 ng/ml soluble IL-6 recep-
tor (sl-IL-6R, Antigenix) with or without 100  nM RvE1, and 
incubated for 48 h. Supernatants were collected, centrifuged at 
4,000 × g for 10 min at 4°C, and frozen at −80°C until assayed. 
RANKL and OPG ELISA kits were purchased from R&D Systems 
(Minneapolis, MN, USA).
Micro cT
Samples were placed in a standardized sample holder and scanned 
using high-resolution Micro CT (μCT) (Scanco Medical, Brütti-
sellen, Sweden) at a spatial resolution of 18.676 µm (voxel dimen-
sion) with 1,536 ×  1,536-pixel matrices. The two-dimensional 
image data were stored in Digital Imaging and Communications 
in Medicine format and transferred to a computer for three-
dimensional reconstruction and analyses.
Murine calvarial regions were cropped from consecutive 
slice images as volume of interest (VOI) using Amira software 
(VSG|FEI Visualization Sciences Group, Burlington, MA, USA). 
The volume of new bone was measured within a digital VOI 
accor ding to teeth dimensions. Volumetric analysis was evaluated 
by global thresholding procedures (bone tissue = 3,409–10,913). 
Total bone volume (BV) is presented as mean and SD of voxel 
units calculated by Amira (45). Statistical significance was deter-
mined by analysis of variance (ANOVA) and multiple compa-
risons were corrected by the Holm–Sidak method (significance 
at p < 0.05).
statistics
Comparisons between the three in  vivo groups and the four 
in vitro groups were analyzed by one-way ANOVA followed by 
post  hoc analysis (with Bonferroni adjustment in the pairwise 
t-test function). All values were expressed as mean SEM. p-Value 
lower than 0.05 was considered statistically significant.
resUlTs
rve1 Promotes In Vivo Bone regeneration
To investigate if daily TNF-α injections induced calvarial oste-
olysis in mice, surface porosity (SP) and BV measurements were 
conducted by μCT using Amira 3D software to measure and 
quantify peaks and valleys on calvarial surfaces. The ratio of SP 
to BV was measured to standardize the BV being tested for SP. 
A significant increase in SP/BV ratio was observed in specimens 
from the TNF-α group compared to both negative control and 
RvE1 treatment groups (p < 0.03) (Figure 1A).
rve1 reduces Osteoclastogenesis 
Triggered by TnF-α injections
The number of TRAP-stained multinucleated giant cells (MNGCs) 
in the suture area in each section, as well as the number of nuclei 
per MNGC found in each section was analyzed (Figure  1B). 
The adjusted mean number of nuclei/cell/section was calculated 
by dividing the number of nuclei by the number of MNGCs found 
in each section. A statistically significant increase in number of 
MNGCs and nuclei/MNGC was observed in sections from sam-
ples receiving TNF-α injections compared to samples receiving 
PBS injections (p < 0.05). A statistically significant decrease was 
observed in samples from animals in the RvE1 treatment group 
compared to the TNF-α group (p < 0.05).
rve1 Modulates In Situ expression  
of OPg and ranKl
The same sections from each group were double stained with 
Alexa Fluor 488 for RANKL and OPG monoclonal mouse anti-
bodies conjugated with Dylight 550 dye (Figure 2A). In the RvE1 
treatment group, mean RANKL immunofluorescence was lower 
than the TNF-α group. This difference was statistically significant 
(p < 0.05). Evaluation of mean OPG immunofluorescence values 
revealed no statistically significant differences between the three 
groups (p > 0.05).
rve1 Modulates ranKl expression  
in Osteoblasts
Resolvin E1 at 100 nM significantly decreased RANKL produc-
tion by osteoblasts stimulated by IL-6 (p <  0.05) (Figure  2B). 
RvE1 had no statistically significant effect on OPG production. 
RvE1 had also no effect on OPG and RANKL in the absence of 
IL-6. However, in the presence of IL-6, RANKL levels significantly 
increased and were reduced back to control levels after RvE1 at 
100 nM was added (p < 0.05). Comparing the RANKL/OPG ratio 
between groups revealed a significant increase after the addition 
of IL-6 compared to negative controls. This increase was statisti-
cally significant (p < 0.05). Treatment with RvE1 at 100 nM led 
to a significant reduction in the RANKL/OPG ratio (p < 0.05). 
No significant difference was found between the groups with 
cells alone, when compared to cells with RvE1 alone. The results 
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indicated that RvE1 suppresses levels of RANKL via direct action 
on osteoblasts leading to a shift in the RANKL/OPG ratio in favor 
of bone preservation and formation.
rve1 Differentially regulates gene 
expression Under inflammatory 
conditions
A heat map (Figure 3) demonstrating the top 100 differentially 
expressed genes (absolute log2 fold change) under different expe-
rimental conditions was constructed. The result demonstrated a 
remarkable mirror image change in gene expression in cells under 
inflammatory conditions and after RvE1 treatment. After RvE1 
treatment, genes that were downregulated by the addition of IL6 
were upregulated. Similarly, genes that were upregulated by IL-6 
were downregulated after RvE1 treatment.
We then examined osteoclast differentiation pathway per-
turbation (Figure 4) after stimulation with IL-6 with or without 
100 nM of RvE1. IL-6 caused an upregulation of IL-1 promoting 
a series of downstream signals affecting the MAPK and NFκB 
signaling pathways leading to upregulation of osteoclast differ-
entiation. The addition of RvE1 led to downregulation of STAT1 
and downstream signaling leading to suppression of osteoclast 
differentiation.
Using Illumina’s iPathway Guide impact analysis tool (43, 44), 
we identified the biological pathways with the most significant 
perturbation and overrepresentation combination (Figure 5). The 
extracellular matrix (ECM) receptor interactions were found to 
be the most significant. Under inflammatory conditions, expres-
sion of ECM receptors aids in inflammatory cellular migration 
and adhesion. After stimulation with IL-6, osteoblasts demon-
strate a significant upregulation of ECM receptors (Figure 6A). 
FigUre 6 | Continued
FigUre 6 | Continued
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FigUre 6 | Continued
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This upregulation leads to a high fold change in the level of ECM 
receptor interaction perturbation. After treatment with 100 nM 
of RvE1, a significant downregulation of the ECM interactions 
is noted, which promoted a high-fold downregulation in the 
level of ECM receptor interaction perturbation (Figure 6B). The 
PI3K–AKT pathway also showed a significant perturbation in 
response to treatment of IL-6 stimulated osteoblasts with RvE1 
(Figure  7). Treatment with RvE1 significantly impacted the 
PI3K–AKT by regulating multiple upstream and downstream 
targets and thereby affecting multiple cell functions including 
differentiation, protein synthesis, and apoptosis. These interac-
tions also influence the NFκB, MAPK, and p53 signaling pathways. 
We further conducted a meta-analysis on differential gene exp-
ression under the three experimental conditions, comparing 
cells +  IL-6 vs. cells alone, IL-6 + RvE1 vs. cells alone and 
cells + IL-6 + RvE1 vs. cells + IL-6. We isolated 14 genes that were 
significantly differentially regulated after stimulation with IL-6 
whose regulation was significantly reversed by RvE1 treatment 
(Tables 1 and 2; Figure 8).
DiscUssiOn
Inflammation and bone remodeling are inseparable processes; 
however, little is known about the details of interaction between 
the immune response and bone. Clearly, certain inflammatory 
cytokines are known to have direct actions on bone (IL-1 and 
IL-6), but the cellular mechanisms that regulate these actions 
are poorly understood. It has been demonstrated that in 
FigUre 6 | Continued
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FigUre 6 | (a) Perturbation in extracellular matrix (ECM) receptor interactions in response to stimulation of osteoblasts with interleukin (IL)-6. Using Illumina’s 
iPathwayGuide, we evaluated the perturbation in ECM receptor interactions. Under inflammatory conditions, expression of ECM receptors aids in inflammatory 
cellular migration and adhesion. The diagram demonstrates a significant upregulation of ECM receptor interactions in response to stimulation of osteoblasts with 
IL-6. (B) Perturbation in ECM receptor interactions in response to resolvin E1 (RvE1) treatment after stimulation of osteoblasts with IL-6. The diagram demonstrates 
a significant downregulation of ECM receptor interactions in response to 100 nM RvE1 treatment after stimulation of osteoblasts with IL-6.
12
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FigUre 7 | PI3K–AKT pathway perturbation in response to treatment of interleukin (IL)-6 stimulated osteoblasts with resolvin E1 (RvE1). The perturbation 
demonstrates that RvE1 influences PI3K–AKT by regulating multiple upstream and downstream targets and thereby affecting multiple cell functions including 
differentiation, protein synthesis, and apoptosis. These interactions also influence the NFκB, MAPK, and p53 signaling pathways.
inflammatory dis eases the RANKL/OPG ratio is consistently 
elevated (46, 47). RANKL is the primary signal for osteoclastic 
differen tiation, while OPG acts as a decoy receptor that inhibits 
RANKL–RANK binding and thus decreases osteoclastogenesis. 
Therefore, the RANKL/OPG ratio drives osteoclastogenesis and 
osteoclast activation (48).
To evaluate whether the regulation of the RANKL/OPG ratio by 
RvE1 is partially due to direct actions on bone cells or not, primary 
neonatal osteoblasts were isolated from calvariae of WT mice. 
Neonatal mouse osteoblasts, in response to inflammation, have been 
shown to stimulate the release of RANKL (49) and inhibit secretion 
of its decoy receptor OPG (50), promoting osteoclastogenesis and 
bone resorption (51). Two separate research groups have indepen-
dently demonstrated that osteoblasts express chemR23 receptor (52, 
53). Our in vitro finding that RvE1 acts directly on osteoblasts to 
decrease the RANKL levels, elevated under inflammatory conditions 
is, to the best of our knowledge, a novel finding. These observations 
confirmed earlier findings that RvE1 regulates the RANKL–OPG 
ratio to favor bone preservation (53). It also provides a clarification 
that RvE1 treatment of bone marrow-derived primary osteoclast 
cultures results in a decrease of osteoclastic maturation and thereby 
decreased bone resorption in vitro (54).
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TaBle 1 | List of genes differentially regulated by RvE1 treatment.
gene logfc logfc
[interleukin (il)-6 vs. control] p Value (il6rve1 vs. il6) p Value
Actg2 −0.844 0.006 1.248 0.043
Adh1 −0.964 0.008 1.383 0.000
Atoh8 −1.054 0.000 1.408 0.000
Csrp2 −0.793 0.002 1.156 0.046
Gas6 −0.749 0.010 0.794 0.040
Gpx3 −1.025 0.000 1.200 0.002
Gstt1 −0.925 0.011 1.153 0.041
Ifi44 0.774 0.001 −1.700 0.000
Ifit1 0.688 0.044 −1.601 0.000
Mfap2 −0.998 0.000 1.302 0.003
Myl9 −0.945 0.006 1.353 0.023
Rbp1 −0.944 0.000 1.073 0.045
S100b −0.748 0.030 1.094 0.002
Tgfb3 −0.684 0.040 1.162 0.014
TaBle 2 | Actions of genes significantly regulated by RvE1 treatment.
gene symbol iD Title summary of actions
Actg2 25365 Actin, gamma 2, smooth muscle, enteric May play a role in smooth muscle function
Adh1 24172 Alcohol dehydrogenase 1 Alpha subunit of class I alcohol dehydrogenase; metabolizes a wide variety of substrates 
including ethanol, hydroxysteroids, and lipid peroxidation products
Atoh8 500200 Atonal bHLH transcription factor 8 Regulates skeletal myogenesis
Csrp2 29317 Cysteine and glycine-rich protein 2 May act as an adaptor molecule in the JAK/STAT signaling pathway
Gas6 58935 Growth arrest specific 6 Provides protection of neurons against serum deprivation-induced apoptosis
Gpx3 64317 Glutathione peroxidase 3 The protein encoded by this gene belongs to the glutathione peroxidase family, members of 
which catalyzes the reduction of organic hydroperoxides and hydrogen peroxide (H2O2) by 
glutathione, and thereby protect cells against oxidative damage
Gstt1 25260 Glutathione S-transferase theta 1 Subunit of the glutathione S-transferase
Ifi44 310969 Interferon-induced protein 44 Unknown
Ifit1 56824 Interferon-induced protein with 
tetratricopeptide repeats 1
Responses to dexamethasone and other inflammatory stimuli
Mfap2 313662 Microfibril associated protein 2 Unknown
Myl9 296313 Myosin light chain 9 Unknown
Rbp1 25056 Retinol binding protein 1 Binds and transports retinol; plays a role in vitamin A metabolism 
S100b 25742 S100 calcium binding protein B Binds GTPase activating protein IQGAP1; may play a role in cell membrane rearrangement
Tgfb3 25717 Transforming growth factor, beta 3 Involved in epithelial and endothelial cell proliferation and differentiation during development
Animal and human trials have demonstrated that regular 
diets rich in ω-3 PUFA result in a reduction in bone turnover 
and an increase bone mineral density (55–58). However, the 
exact mechanism of action of ω-3 PUFA on a molecular level 
is still not completely clear. In bone marrow samples harvested 
from rats fed a diet supplemented with EPA, elevated levels 
of RvE1 have been noted (59). Our findings demonstrate that 
RvE1, the active metabolite of EPA, impacts bone remodeling 
under inflammatory conditions and that this impact is, in part, 
due to a direct action on bone cells. Our RNA-Seq and differ-
ential expression analysis data enabled us to understand more 
about the receptors and signaling pathways through which 
RvE1 directly acts on osteoblasts. RvE1 differentially regulated 
gene expression in response to inflammation and reversed gene 
expression levels back to homeostasis levels. We also isolated 
pathways with significant overrepresentation and perturbation 
in response to IL-6 stimulation with or without RvE1. The 
osteoclast differentiation pathway showed perturbation after 
stimulation with IL-6 with or without 100  nM of RvE1. Our 
perturbation analysis revealed that this might be partially due 
to a sharp upregulation of IL-1 expression, which promoted a 
series of downstream signaling events affecting the MAPK and 
NFκB signaling pathways promoting upregulation of osteoclast 
differentiation. After the addition of RvE1, a downregulation of 
STAT1 led to downregulation of same downstream signaling 
pathways affected by IL-6 through IL-1, in both the MAPK 
and NFκB pathways. This highlighted the need to look at the 
broader actions of pro-resolution molecules and how they 
regulate different pathways through collateral signaling. We 
identified that the ECM receptor interaction pathway showed 
significant perturbation and over representation in response 
to IL-6 and after treatment with RvE1. ECM receptor interac-
tions were sharply upregulated after stimulation with IL-6. This 
finding is consistent with our current knowledge of the role 
played by ECM in modulating inflammation (60). In addition 
to acting as a scaffold or barrier for cells infiltra ting inflamed 
tissues, ECM regulates inflammatory cell migration through 
endothelial basement membranes, provides specific signaling 
to immune cells to identify their exit sites in venules, as well as 
regulating their ability to promote the inflammatory response 
(60). Treatment with RvE1 appears to have reversed the upregu-
lation of ECM receptor interactions induced by IL6 suggesting 
a return to homeostasis. The PI3K–AKT pathway showed a 
significant perturbation in response to treatment of IL-6 stimu-
lated osteoblasts with RvE1 (Figure 7). RvE1 acted on multiple 
upstream and downstream targets of AKT affecting multiple 
cell functions including differentiation, protein synthesis, and 
apoptosis. These interactions also influenced the NFκB, MAPK, 
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FigUre 8 | Meta analysis of differential gene expression. We identified a group of 14, which were significantly differentiated (upregulated/downregulated) genes after 
induction of inflammation and were significantly reversed after treatment with resolvin E1 (RvE1). For a list of genes and their functions see Tables 1 and 2.
and p53 signaling pathways. These findings confirm results by 
Ohira et al. showing that RvE1 stimulated phosphorylation of 
AKT that was both ligand and receptor dependent (61). They 
also are consistent with Berg et al.’s findings, that stimulation 
of chemR23 with the agonist chemerin resulted in downstream 
Akt and MAPK phosphorylation, as well as elevated levels of 
pro-inflammatory cytokines (62). The downregulation of Gas6 
after stimulation with IL-6 and its upregulation after treat-
ment with RvE1 is consistent with reported patterns of Gas6 
expression. Gas6 has been shown to decrease the production of 
pro-inflammatory cytokines (63).
Chemokine like receptor 1 (ChemR23 or CMKL1) receptors for 
RvE1 have been identified on monocytes (64). These molecules 
also serve as receptors for chemerin (65, 66). Moreover, ChemR23 
was found to be expressed in other tissues, such as renal, cerebral, 
gastrointestinal, and cardiovascular tissues (52, 67). Its inhibi-
tion of TNF-α stimulated NFκB activation seems to be directly 
related to its ability to specifically bind RvE1 (30). The specific 
mechanism by which pro-resolution molecules, downregulate 
bone loss during the course of inflammatory diseases is partially 
known (53), but how resolvins, specifically RvE1, directly impact 
bone cells is still poorly understood. The finding that ChemR23 
is expressed in developing bone tissue might indicate a role in 
bone formation (68).
Together, our results provide evidence for RvE1’s direct impact 
on the skeletal system; regulating pathologic inflammation-
indu ced bone resorption by control of the RANKL/OPG ratio 
and downstream genetic events.
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